Investment analysts at StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a report issued on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
Shares of NASDAQ:TTNP opened at $3.25 on Wednesday. Titan Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $14.80. The business’s 50 day simple moving average is $3.47 and its 200-day simple moving average is $4.59.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Find and Profitably Trade Stocks at 52-Week Lows
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- How Can Investors Benefit From After-Hours Trading
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
